<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02144987</url>
  </required_header>
  <id_info>
    <org_study_id>1101-C-092-JS</org_study_id>
    <nct_id>NCT02144987</nct_id>
  </id_info>
  <brief_title>Bone Marrow Stem Cell Treatment for Asherman's Syndrome and Endometrial Atrophy</brief_title>
  <acronym>BMSCT</acronym>
  <official_title>New Therapeutic Approaches to Treat Asherman's Syndrome and Endometrial Atrophy Based in BM Stem Cells Autologous Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Valenciano de Infertilidad, IVI VALENCIA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundación para la Investigación del Hospital Clínico de Valencia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto Valenciano de Infertilidad, IVI VALENCIA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Bone Marrow Stem Cell transplantation may
      improve Assisted Reproduction Techniques (ART) outcomes in refractive Asherman's Syndrome or
      Atrophic Endometrium.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This novel technique refers to the use of CD133+ autologous bone marrow stem-cells to
      regenerate the endometrium in patients with Asherman's Syndrome, Endometrial Atrophy or any
      condition that produce a destruction of the endometrium or its de novo creation in a
      bioengineered uterus.

      It requires a previous mobilization in the peripheral blood of CD133+ autologous bone marrow
      stem cells, subsequent apheresis and transplant of the same cells in the spiral arterioles of
      the uterus with the aim to regenerate de novo the endometrium. This technique represents a
      new therapeutical approach for the treatment of endometrial regeneration problems such
      Asherman Syndrome and the endometrial atrophy since currently no specific treatment for these
      endometrial pathologies exist.

      A prospective experimental non controlled study has been designed in order to assess the
      effectiveness of these technique as a new tool for treat Asherman's Syndrome and Endometrial
      Atrophy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Live-birth rate</measure>
    <time_frame>15 months</time_frame>
    <description>Live birth rate is the percentage of all cycles that lead to live birth, and is the pregnancy rate adjusted for miscarriages and stillbirths.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ongoing pregnancy rate</measure>
    <time_frame>9 months</time_frame>
    <description>Ongoing pregnancy rate is the percentage of all cycles that lead to presence of heartbeat in Ultrasound scan at the end of the first trimester</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Implantation Rate</measure>
    <time_frame>6 months</time_frame>
    <description>Implantation rate is the percentage of embryos which successfully undergo implantation compared to the number of embryos transferred in a given period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endometrial thickness prior to the treatment</measure>
    <time_frame>0</time_frame>
    <description>Endometrial thickness measured with Ultrasound in a previous treatment with Hormonal Replacement Therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endometrial Thickness after treatment</measure>
    <time_frame>3-6 months</time_frame>
    <description>Endometrial thickness measured with Ultrasound with Hormonal Replacement Therapy 3-6 months after Bone Marrow Stem Cell Transplantation</description>
  </secondary_outcome>
  <enrollment type="Actual">16</enrollment>
  <condition>Asherman's Syndrome</condition>
  <condition>Endometrium; Atrophy, Cervix</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bone Marrow CD133+ Stem Cell Transplantation</intervention_name>
    <description>Bone Marrow Stem Cell (BMSC) mobilization peripheral blood induced by granulocyte-CSF (G-CSF) 5 mcg/kg sc every 12 hours for 4 days.
BMSC recollection with apheresis procedure and positive selection of the CD133+ cells.
The selection procedure will be performed for a maximum of 3 hours or until at least 50 million cells are collected.
CD133+ cells transplantation into the uterine spiral arterioles by intra-arterial catheterization
Subsequently Hormonal Replacement Therapy (HRT) will be given to the patients
Hysteroscopy will be performed 2-3 months after stem cell transplantation
Embryo transfer will be performed 3-6 months after stem cell transplantation with HRT endometrial preparation</description>
    <other_name>Neupogen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed of Asherman Syndrome and absence of pregnancy after treatment

          -  Endometrial atrophy (&lt;6mm) with Implantation Failure

          -  Age 20-45 years-old

          -  Normal liver, heart and kidney function

          -  Presence of menstrual bleeding with Natural Cycle or HRT

          -  Absence of psychiatric pathology and ability to accomplish the treatment

          -  β-hCG negative

          -  Absence of SDT

        Exclusion Criteria:

          -  Absence of peripheral vein access

          -  Lack of accomplish inclusion criteria
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xavier Santamaria, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Valenciano Infertilidad</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlos Simon, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Valenciano Infertilidad</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clinico y Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano Infertilidad</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Chan RW, Schwab KE, Gargett CE. Clonogenicity of human endometrial epithelial and stromal cells. Biol Reprod. 2004 Jun;70(6):1738-50. Epub 2004 Feb 6.</citation>
    <PMID>14766732</PMID>
  </reference>
  <reference>
    <citation>Cervelló I, Gil-Sanchis C, Mas A, Faus A, Sanz J, Moscardó F, Higueras G, Sanz MA, Pellicer A, Simón C. Bone marrow-derived cells from male donors do not contribute to the endometrial side population of the recipient. PLoS One. 2012;7(1):e30260. doi: 10.1371/journal.pone.0030260. Epub 2012 Jan 19.</citation>
    <PMID>22276168</PMID>
  </reference>
  <reference>
    <citation>Ikoma T, Kyo S, Maida Y, Ozaki S, Takakura M, Nakao S, Inoue M. Bone marrow-derived cells from male donors can compose endometrial glands in female transplant recipients. Am J Obstet Gynecol. 2009 Dec;201(6):608.e1-8. doi: 10.1016/j.ajog.2009.07.026. Epub 2009 Oct 3.</citation>
    <PMID>19800602</PMID>
  </reference>
  <reference>
    <citation>Taylor HS. Endometrial cells derived from donor stem cells in bone marrow transplant recipients. JAMA. 2004 Jul 7;292(1):81-5.</citation>
    <PMID>15238594</PMID>
  </reference>
  <reference>
    <citation>Cervelló I, Mas A, Gil-Sanchis C, Peris L, Faus A, Saunders PT, Critchley HO, Simón C. Reconstruction of endometrium from human endometrial side population cell lines. PLoS One. 2011;6(6):e21221. doi: 10.1371/journal.pone.0021221. Epub 2011 Jun 21.</citation>
    <PMID>21712999</PMID>
  </reference>
  <reference>
    <citation>Nagori CB, Panchal SY, Patel H. Endometrial regeneration using autologous adult stem cells followed by conception by in vitro fertilization in a patient of severe Asherman's syndrome. J Hum Reprod Sci. 2011 Jan;4(1):43-8. doi: 10.4103/0974-1208.82360.</citation>
    <PMID>21772740</PMID>
  </reference>
  <reference>
    <citation>March CM. Management of Asherman's syndrome. Reprod Biomed Online. 2011 Jul;23(1):63-76. doi: 10.1016/j.rbmo.2010.11.018. Epub 2010 Dec 4. Review.</citation>
    <PMID>21549641</PMID>
  </reference>
  <reference>
    <citation>Zhang X, Chen CH, Confino E, Barnes R, Milad M, Kazer RR. Increased endometrial thickness is associated with improved treatment outcome for selected patients undergoing in vitro fertilization-embryo transfer. Fertil Steril. 2005 Feb;83(2):336-40.</citation>
    <PMID>15705371</PMID>
  </reference>
  <reference>
    <citation>Sanz-Ruiz R, Gutiérrez Ibañes E, Arranz AV, Fernández Santos ME, Fernández PL, Fernández-Avilés F. Phases I-III Clinical Trials Using Adult Stem Cells. Stem Cells Int. 2010 Nov 4;2010:579142. doi: 10.4061/2010/579142.</citation>
    <PMID>21076533</PMID>
  </reference>
  <reference>
    <citation>Mäkelä J, Anttila V, Ylitalo K, Takalo R, Lehtonen S, Mäkikallio T, Niemelä E, Dahlbacka S, Tikkanen J, Kiviluoma K, Juvonen T, Lehenkari P. Acute homing of bone marrow-derived mononuclear cells in intramyocardial vs. intracoronary transplantation. Scand Cardiovasc J. 2009 Dec;43(6):366-73. doi: 10.1080/14017430903045350.</citation>
    <PMID>19544220</PMID>
  </reference>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2014</study_first_submitted>
  <study_first_submitted_qc>May 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2014</study_first_posted>
  <last_update_submitted>April 21, 2015</last_update_submitted>
  <last_update_submitted_qc>April 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Gynatresia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

